Compile Data Set for Download or QSAR
maximum 50k data
Report error Found 21 Enz. Inhib. hit(s) with all data for entry = 5931
TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101226(US8524722, 5)
Affinity DataIC50:  1nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101231(US8524722, 31)
Affinity DataIC50:  1nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101239(US8524722, 119)
Affinity DataIC50:  1nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101240(US8524722, 123)
Affinity DataIC50:  1nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101228(US8524722, 12)
Affinity DataIC50:  1nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101230(US8524722, 14)
Affinity DataIC50:  1nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101243(US8524722, 143)
Affinity DataIC50:  1nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101237(US8524722, 90)
Affinity DataIC50:  1nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101232(US8524722, 70)
Affinity DataIC50:  1nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101241(US8524722, 134)
Affinity DataIC50:  1nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101227(US8524722, 10)
Affinity DataIC50:  1.10nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101234(US8524722, 84)
Affinity DataIC50:  1.40nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101229(US8524722, 13)
Affinity DataIC50:  2nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101244(US8524722, 148)
Affinity DataIC50:  4.30nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM50330241((E)-4-(Dimethylamino)-1-(4-[(1R)-1-phenylethyl]ami...)
Affinity DataIC50:  4.60nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101235(US8524722, 86)
Affinity DataIC50:  5nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101245(US8524722, 151)
Affinity DataIC50:  6.40nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101242(US8524722, 139)
Affinity DataIC50:  9.20nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101238(US8524722, 95)
Affinity DataIC50:  10nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101233(US8524722, 81)
Affinity DataIC50:  12nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetEpidermal growth factor receptor(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM101236(US8524722, 87)
Affinity DataIC50:  19nMpH: 7.0 T: 22°CAssay Description:EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.More data for this Ligand-Target Pair
In DepthDetails US Patent